CARGO Therapeutic announced that it has elected to discontinue FIRCE-1, a Phase 2 clinical study of firi-cel for patients with large B-cell lymphoma whose disease relapsed or was refractory to CD19 ...

CARGO elects to discontinue FIRCE-1, a Phase 2 clinical study of firicabtagene autoleucel (firi-cel)1; Company believes results do not support a ...

US clinical-stage biotech CARGO Therapeutics’ shares plummeted more than 75% to $3.23 yesterday, after it announced that it ...

CARGO Therapeutics, Inc. announced the discontinuation of its FIRCE-1 Phase 2 clinical study of firicabtagene autoleucel (firi-cel) for large B-cell lymphoma due to safety concerns and ...

SAN CARLOS, Calif. - CARGO Therapeutics , Inc. (NASDAQ:CRGX), a clinical-stage biotech company currently valued at $628 ...

Truist Securities revised its position on Cargo Therapeutics (NASDAQ:CRGX), currently trading at $13.19 with a market ...

CARGO Therapeutics, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - CRGX ...

CARGO elects to discontinue FIRCE-1, a Phase 2 clinical study of firicabtagene autoleucel (firi-cel)1; Company believes results do not support a competitive benefit-risk profile for patients.

Further, CARGO will continue to advance CRG-023 ... We are grateful for the patients, caregivers and families who were involved in the FIRCE-1 study, as well as the investigators who partnered ...

CARGO elects to discontinue FIRCE-1, a Phase 2 clinical study of firicabtagene autoleucel (firi-cel)1; Company believes results do not support a competitive benefit-risk profile for patients.

CARGO Therapeutics, Inc. (Nasdaq: CRGX), a clinical-stage biotechnology company advancing next generation, potentially curative cell therapies for cancer patients, today announced that it has elected ...